 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || SHR-A2009 / Jiangsu Hengrui Pharma
Trial completion, Trial completion date, Trial primary completion date: SHR-A2009-I-102: The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 27, 2024
P1, N=19, Completed, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Apr 2024 | Trial primary completion date: Jun 2025 --> Apr 2024
- |||||||||| SHR-A2009 / Jiangsu Hengrui Pharma
New P3 trial, Metastases: A Study of SHR-A2009 Versus Platinum-based Chemotherapy in EGFR-mutated, Advanced or Metastatic NSCLC (clinicaltrials.gov) - Nov 4, 2024
P3, N=500, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- | New P2 trial: Platform Study of ADC Rechallenge in ADC-treated Metastatic Breast Cancer (clinicaltrials.gov) - Oct 17, 2024
P2, N=120, Recruiting, Sponsor: Fudan University
- | Enrollment change: BCTOP-L-M05: SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov) - Oct 4, 2024
P2, N=620, Recruiting, Sponsor: Fudan University
Active, not recruiting --> Completed | Trial completion date: Jun 2026 --> Apr 2024 | Trial primary completion date: Jun 2025 --> Apr 2024 N=140 --> 620
- | Trial completion date: CAP 02: A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Sep 19, 2024
P2, N=147, Recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
N=140 --> 620 Trial completion date: Dec 2024 --> Dec 2025
- |||| SHR-9839 / Jiangsu Hengrui Pharma
New P1/2 trial, Combination therapy, Metastases: A Phase IB/II Clinical Study of SHR-9839 for Injection Combined With Other Anti-tumor Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Jun 25, 2024
P1/2, N=156, Not yet recruiting, Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- | SHR-A2009 / Jiangsu Hengrui Pharma, tizetatug rezetecan (SHR-A1921) / Jiangsu Hengrui Pharma
New P2 trial, Metastases: Clinical Study of SHR-A1921 or SHR-A2009 in Previously Treated Advanced NSCLC (clinicaltrials.gov) - Jun 18, 2024
P2, N=30, Not yet recruiting, Sponsor: Henan Cancer Hospital
- | Enrollment change, Trial completion date: CAP 02: A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Feb 15, 2024
P2, N=125, Recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
Trial completion date: Dec 2024 --> Dec 2025 N=85 --> 125 | Trial completion date: Feb 2023 --> Dec 2024
- ||||| HRS-8080 / Jiangsu Hengrui Pharma, SHR-A2009 / Jiangsu Hengrui Pharma
New P1/2 trial, Metastases: Study of HRS-8080 or SHR-A2009 Combined With Anti-tumor Therapy in Patients With Unresectable or Metastatic Breast Cancer (clinicaltrials.gov) - Jan 24, 2024
P1/2, N=350, Not yet recruiting, Sponsor: Shandong Suncadia Medicine Co., Ltd.
- ||||| SHR-A2009 / Jiangsu Hengrui Pharma
New P1/2 trial, Combination therapy, Metastases: SHR-A2009-201: A Phase IB/II Clinical Study of SHR-A2009 for Injection in Combination With Other Antitumor Therapies in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 23, 2023
P1/2, N=270, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- || SHR-A2009 / Jiangsu Hengrui Pharma
Enrollment closed, Enrollment change: SHR-A2009-I-102: The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 16, 2023
P1, N=19, Active, not recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
N=85 --> 125 | Trial completion date: Feb 2023 --> Dec 2024 Recruiting --> Active, not recruiting | N=172 --> 19
- SHR-A2009 / Jiangsu Hengrui Pharma
Phase I study of SHR-A2009, a HER3-targeted ADC, in advanced solid tumors (Valencia Auditorium - Hall 10) - Jul 27, 2023 - Abstract #ESMO2023ESMO_1369;
P1
Conclusions SHR-A2009 showed a tolerable safety profile and encouraging anti-tumor activity in pts with heavily pretreated advanced solid tumors. The trial is ongoing to assess SHR-A2009 at higher doses and in selected cancer types (NSCLC and other solid tumors).
- | Enrollment open: BCTOP-L-M05: SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov) - Jan 4, 2023
P2, N=140, Recruiting, Sponsor: Fudan University
The trial is ongoing to assess SHR-A2009 at higher doses and in selected cancer types (NSCLC and other solid tumors). Not yet recruiting --> Recruiting
- | New P2 trial: BCTOP-L-M05: SNF Platform Study of HR+/ HER2-advanced Breast Cancer (clinicaltrials.gov) - Oct 26, 2022
P2, N=140, Not yet recruiting, Sponsor: Fudan University
- ||| SHR-A2009 / Jiangsu Hengrui Pharma
Enrollment open: SHR-A2009-I-102: The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Oct 21, 2022
P1, N=172, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| SHR-A2009 / Jiangsu Hengrui Pharma
Enrollment open: SHR-A2009-I-101: A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Sep 28, 2022
P1, N=132, Recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Not yet recruiting --> Recruiting Not yet recruiting --> Recruiting
- ||| SHR-A2009 / Jiangsu Hengrui Pharma
New P1 trial: SHR-A2009-I-102: The Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - May 26, 2022
P1, N=172, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- | Enrollment change, Trial completion date: CAP 02: A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Apr 18, 2022
P2, N=85, Recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
Not yet recruiting --> Recruiting N=52 --> 85 | Trial completion date: Dec 2021 --> Dec 2022
- ||| SHR-A2009 / Jiangsu Hengrui Pharma
New P1 trial: SHR-A2009-I-101: A Phase I Clinical Study of SHR-A2009 for Injection in Patients With Advanced Solid Tumors (clinicaltrials.gov) - Nov 9, 2021
P1, N=132, Not yet recruiting, Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd.
- | Trial completion date, Trial primary completion date: CAP 02: A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Aug 18, 2021
P2, N=52, Recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
N=52 --> 85 | Trial completion date: Dec 2021 --> Dec 2022 Trial completion date: Apr 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Jun 2021
- | Enrollment open, Trial primary completion date: CAP 02: A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Sep 29, 2020
P2, N=45, Recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University
Trial completion date: Apr 2021 --> Dec 2021 | Trial primary completion date: Dec 2020 --> Jun 2021 Not yet recruiting --> Recruiting | Trial primary completion date: Apr 2020 --> Dec 2020
- | New P2 trial: CAP 02: A Phase II Exploratory Clinical Trial of Multiple Drug Combinations in the Treatment of Advanced Esophageal Squamous Cell Carcinoma (clinicaltrials.gov) - Nov 9, 2018
P2, N=45, Not yet recruiting, Sponsor: The First Affiliated Hospital of Zhengzhou University